We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
Helping SME home builders acquire finance for their projects in the UK. Rubicon Capital has assisted more than 40 project developers in receiving investments for their builds, which has exceeded £75m. In their second year, the company generated £500k in profits and has successfully paid dividends every year since launching in 2015. Two main sources of revenue are upfront fees for connecting borrowers with lenders and administration fees in the form of long-term consultancy and performance assistance. Money raised from this crowdfunding round will be used to expand the Rubicon Capital team and grow their business to attract more home builders requiring financial assistance, in addition to increasing the number of sources offering finance.
days to go: Expired investment: £128,510
BeneTalk is an innovative digital therapeutic solution, providing on-demand support to individuals who stutter and their families, aiming to enhance their quality of life and confidence. Stuttering affects millions globally, and with limited specialized therapy options, BeneTalk addresses accessibility challenges by offering timely assistance, aiming to mitigate the higher risk of low self-esteem and mental health issues faced by individuals who stutter and their families.
days to go: Expired investment: £173,123
Nutrifix is an app that locates healthy meals nearby or selects recipes or delivery options all tailored to you bodies needs. The app is like having a personal nutritionist in your pocket and is in a growing sector as the global value of mobile health solutions is set to reach 83,000,000,000 by 2022.

Pitch Rated

70%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £194,310
HealthBox Software is a technology company building products for the post-COVID healthcare landscape. Its first product, ClearPass, was met with success. The tool asks an employee a series of screening questions related to COVID-19, including evidence of fever, fatigue, and dry cough, etc. ClearPass has over 400,000 end-users including companies like Johnson Controls, Remy Cointreau and the San Diego School District. HealthBox aims to be a significant contender in the global digital health market that is expected to be worth $600 billion by 2026. The company is on the verge of launching another innovative product, MyHealthBox. It is a consumer-facing digital health app that will allow users to store their medical records, easily accessible 24/7. HealthBox asserts that the app will have an array of features, including AI health assessment services, dietary advice and data-powered lifestyle guidance. The company will use 47% of the investment towards technology and development costs, and 53% towards sales and marketing.

Pitch Rated

79%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £144,265
An online marketplace to buy and sell residential investment properties for those looking to generate an extra income. Vesta has sold 104 properties valued at £22m since launching in 2018. Properties listed contain full documents including tenancy history, due diligence, 360-degree photos and videos, valuations and investment projections. Sellers can list various new or existing sites and buyers can range from sole investors to institutions. Vesta generates revenue by charging fees to both sellers and buyers. Various payment options are available to sellers and optional fees are charged to those who wish to host viewings for their properties. Buyers are charged a fixed fee after an offer is accepted. Vesta is now raising funds to expand their team, website and property portfolio by increasing brand awareness from marketing campaigns.
days to go: Expired investment: £622,705
Travala.com is a leading blockchain travel company with over 2 million listings covering 90,124 destinations in 230 countries and territories across the globe. Offering travellers payment options through 20+ cryptocurrencies in addition to credit/debit cards, Travala aims to be 15% cheaper than the rest of the market. Moreover, the company is in strategic partnership with Booking.com. Travala's user base has also increased to over 20K registered users with over 90% organic growth to date. With the proceeds, Travala plans to release its native iOS and Android apps, increase customer support operations worldwide, boost marketing activities, secure more high-profile partnerships from both the blockchain and travel space.

Pitch Rated

65%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £367,580
Lovetovisit is a platform that seamlessly combines inspiration and convenient booking for a wide range of family-friendly activities, ensuring that they enjoy memorable experiences at the best prices. They utilize data-driven content and their proprietary API technology to transform how people discover and purchase tickets for various attractions, events, and experiences. Their mobile-first API technology ensures quick ticket purchases, enhancing convenience. Lovetovisit provides an extensive selection of unique attractions and events, fostering customer loyalty and network effects. Leveraging two decades of supplier relationships, they offer exceptional deals and discounts. The platform is now expanding internationally and enhancing the user experience with video and AI-driven content, continuing to be a mobile-first destination for families seeking affordable and exciting attractions, events, and experiences.
days to go: Expired investment: £328,705
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph